Immune checkpoint inhibitors(ICIs)are currently one of commonly used antitumor drugs in clinical practice,but they may trigger immune checkpoint inhibitor-related pneumonitis(CIP),thereby affecting the clinical benefits of patients.This article systematically analyzed domes-tic and foreign literature and summarized the research progress in the incidence,risk factors,patho-genesis,clinical manifestations,diagnosis,grading,and treatment of CIP.The paper aimed to timely intervene the occurrence and development of CIP and provided a reasonable and effective theoretical basis for the clinical application of ICIs.
维普
万方数据